I-Mab Reports Third Quarter 2024 Results - Nasdaq

Sep 30, 2024 · Third Quarter 2024 Financial Results Cash Position As of September 30, 2024 , the Company had cash and cash equivalents, and short-term investments of $184.4 million , …

CouponFollow Extension

$184
OFF

I-Mab Reports Third Quarter 2024 Results - Nasdaq

1 week from now

Sep 30, 2024 · Third Quarter 2024 Financial Results Cash Position As of September 30, 2024 , the Company had cash and cash equivalents, and short-term investments of $184.4 million , …

nasdaq.com

$184
OFF

I-Mab Reports Third Quarter 2024 Results - Morningstar

1 week from now

2 days ago · Third Quarter 2024 Financial Results. Cash Position. As of September 30, 2024, the Company had cash and cash equivalents, and short-term investments of $184.4 million, …

morningstar.com

$184
OFF

I-Mab Reports Third Quarter 2024 Results

1 week from now

2 days ago · Third Quarter 2024 Financial Results. Cash Position. As of September 30, 2024, the Company had cash and cash equivalents, and short-term investments of $184.4 million, …

i-mabbiopharma.com

$184
OFF

I-Mab Reports Third Quarter 2024 Results - Yahoo Finance

1 week from now

2 days ago · Third Quarter 2024 Financial Results. Cash Position. As of September 30, 2024, the Company had cash and cash equivalents, and short-term investments of $184.4 million, …

yahoo.com

$184
OFF

I-Mab’s Third Quarter Results: Progress In Cancer Immunotherapies

1 week from now

11 hours ago · Key financial highlights reveal I-Mab’s total cash and short-term investments amounted to $184.4 million as of September 30, 2024, providing a financial runway into 2027.

businessinsider.com

$184
OFF

I-Mab Reports Third Quarter 2024 Results | Citybiz

1 week from now

2 days ago · Third Quarter 2024 Financial Results. Cash Position. As of September 30, 2024, the Company had cash and cash equivalents, and short-term investments of $184.4 million, …

citybiz.co

$184
OFF

I Mab : Reports Third Quarter 2024 Results Form 6 K

1 week from now

2 days ago · Estimated cash runway into 2027, based on $184.4 million in cash and cash equivalents, and short-term investments as of September 30, 2024. ROCKVILLE, MD, …

marketscreener.com

$184
OFF

I-Mab Reports Third Quarter 2024 Results - PR Newswire

1 week from now

2 days ago · Third Quarter 2024 Financial Results. Cash Position. As of September 30, 2024, the Company had cash and cash equivalents, and short-term investments of $184.4 million, …

prnewswire.com

$184
OFF

I-Mab Reports Third Quarter 2024 Results | EPICOS

1 week from now

2 days ago · Third Quarter 2024 Financial Results. Cash Position. As of September 30, 2024, the Company had cash and cash equivalents, and short-term investments of $184.4 million, …

epicos.com

$184
OFF

I-Mab Reports Third Quarter 2024 Results

1 week from now

2 days ago · Rhea-AI Summary. I-Mab (NASDAQ: IMAB) reported Q3 2024 financial results and pipeline updates. The company ended Q3 with $184.4 million in cash and equivalents, …

stocktitan.net

FAQs about I-Mab Reports Third Quarter 2024 Results - Nasdaq Coupon?

How much money did I-MAB invest in 2027?

Key financial highlights reveal I-Mab’s total cash and short-term investments amounted to $184.4 million as of September 30, 2024, providing a financial runway into 2027. ...

How much did net interest expense increase in September 30 2024?

Net interest expenses increased to approximately $0.5 million for the three months ended September 30, 2024, from $0.3 million for the three months ended September 30, 2023. Cash and cash equivalents as of September 30, 2024 totaled approximately $49.8 million. ...

What did I-MAB ADR (iMab) do in Q3?

I-Mab Adr ( (IMAB) ) has released its Q3 earnings. Here is a breakdown of the information I-Mab Adr presented to its investors. I-Mab is a U.S.-based global biotechnology company focused on developing innovative immunotherapies for cancer treatment, recognized for its unique approach to targeting tumor microenvironments. ...

What will AMD's revenue look like in Q4 2024?

For the fourth quarter of 2024, AMD expects revenue to be approximately $7.5 billion, plus or minus $300 million. At the mid-point of the revenue range, this represents year-over-year growth of approximately 22% and sequential growth of approximately 10%. Non-GAAP gross margin is expected to be approximately 54%. AMD Teleconference ...

How much did AMD make in the third quarter of 2024?

SANTA CLARA, Calif., Oct. 29, 2024 (GLOBE NEWSWIRE) -- AMD (NASDAQ:AMD) today announced revenue for the third quarter of 2024 of $6.8 billion, gross margin of 50%, operating income of $724 million, net income of $771 million and diluted earnings per share of $0.47. ...

How is I-MAB advancing its uliledlimab and givastomig programs?

Strategically, I-Mab is advancing its uliledlimab and givastomig programs with new phase 2 studies scheduled for 2025. The company also finalized a collaboration agreement with Sanofi and settled previous repurchase obligations, streamlining its operations. ...